Long-Term Efficacy and Safety of Everolimus-Eluting Bioresorbable Vascular Scaffolds Versus Everolimus-Eluting Metallic Stents: A Meta-Analysis of Randomized Trials [Expedited Publication]

Conclusions— Compared with everolimus-eluting stents, BVS is associated with increased risk of target lesion failure driven by the increased rates of target vessel myocardial infarction and ischemia-driven target lesion revascularization in these studies (mean follow-up, 25 months). The risk of definite or probable stent/scaffold thrombosis and very late stent/scaffold thrombosis seems to be higher with BVS. Further information from randomized trials is critical to evaluate clinical outcomes with BVS on complete resolution of the scaffold.

http://circinterventions.ahajournals.org/cgi/content/short/10/5/e005286?rss=1

Source: Circulation: Cardiovascular Interventions - May 3, 2017 Category: Cardiology Authors: Mahmoud, A. N., Barakat, A. F., Elgendy, A. Y., Schneibel, E., Mentias, A., Abuzaid, A., Elgendy, I. Y. Tags: Catheter-Based Coronary and Valvular Interventions Expedited Publication Source Type: research